

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	<b>Application Number</b>		10595587
	<b>Filing Date</b>		2007-01-04
	<b>First Named Inventor</b>	Andrew Lynn	
	<b>Art Unit</b>	1617	
	<b>Examiner Name</b>		
<b>Attorney Docket Number</b>		BOUL 3506	

06/17/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /H.A.R./

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5071436		1991-12-10	Huo et al.	
	2	5320844		1994-06-14	Liu	
	3	5739286		1998-04-14	Silver et al.	
	4	6432710	B1	2002-08-13	Boss, Jr., et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10595587
Filing Date		2007-01-04
First Named Inventor	Andrew Lynn	
Art Unit	1017 1652	
Examiner Name	Hope Robinson	
Attorney Docket Number	BOUL 3506	

06/17/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /H.A.R./

1	0383568	EP	A2	1990-08-22	Norian Corp.	<input type="checkbox"/>
2	0842670	EP	A1	1998-05-20	Nishihara	<input type="checkbox"/>
3	0016822	WO	A1	2000-03-30	Brigham & Womens Hospital	<input type="checkbox"/>
4	63229058	JP		1988-09-22	Oton et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	<del>Abstract of JP No. 63229058, 1998-09-22</del>	<input type="checkbox"/>
	2	SERRE ET AL., "Influence of magnesium substitution on a collagen-apatite biomaterial on the production of a calcifying matrix by human osteoblasts", Journal of Biomedical Materials Research, Dec. 15, 1998, pages 626-633, Vol. 42, No. 4	<input type="checkbox"/>
	3	HEMMERLE ET AL., "Long-term behaviour of a hydroxyapatite/collagen-glycosaminoglycan biomaterial used for oral surgery: a case report", Journal of Materials Science: Materials in Medicine, June 1995, pages 360-366, Vol. 6, No. 6	<input type="checkbox"/>
	4	BAKOS ET AL., "Hydroxyapatite-collagen-hyaluronic acid composite", Biomaterials, January 1999, pages 191-195, Vol. 20, No. 2, Elsevier Science Publishers	<input type="checkbox"/>
	5	ROVIRA ET AL, "Microstructural characterization of a calcium phosphate ESP-collagen composite", Seventh European Conference on Composite Materials. Realising Their Commercial Potential, London, UK, May 14-16, 1996, pages 449-454, Vol. 2	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10595587
Filing Date	2007-01-04
First Named Inventor	Andrew Lynn
Art Unit	<del>1647</del> 1652
Examiner Name	Hope Robinson
Attorney Docket Number	BOUL 3506

**EXAMINER SIGNATURE**

Examiner Signature	/Hope Robinson/	Date Considered	06/17/2009
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.